Tumor necrosis factor alpha as an endogenous stimulator for circulating coupling factor 6

Area of Science:

• Endocrinology
• Molecular Biology
• Cell Biology

Background:

• Mitochondrial coupling factor 6 (CF6) acts as a pressor substance and prostacyclin inhibitor in circulation.
• The regulatory mechanisms governing circulating CF6 levels remain largely unknown.

Purpose of the Study:

• To investigate the role of tumor necrosis factor-alpha (TNF-alpha) in the generation and release of CF6.
• To elucidate the signaling pathways involved in TNF-alpha-mediated CF6 regulation.

Main Methods:

• Utilized human umbilical vein endothelial cells (HUVEC) and ECV-304 cell lines.
• Assessed CF6 release and mitochondrial content via Western blot and ELISA.
• Quantified CF6 mRNA expression using real-time PCR.
• Investigated signaling pathways via dominant-negative I kappa B kinase alpha transfection and NF-kappa B p65 translocation assays.
• Analyzed cell surface CF6 expression using flow cytometry.

Main Results:

• TNF-alpha treatment dose-dependently enhanced CF6 release and decreased mitochondrial CF6 content in HUVEC and ECV-304 cells.
• CF6 gene expression, measured by the ratio of CF6 to GAPDH mRNA, increased significantly after TNF-alpha exposure.
• Dominant-negative I kappa B kinase alpha transfection suppressed TNF-alpha-induced CF6 release and gene expression by 70%.
• TNF-alpha treatment led to a dose-dependent increase in cell surface-associated CF6.

Conclusions:

• TNF-alpha stimulates CF6 gene expression through the activation of the NF-kappa B signaling pathway.
• TNF-alpha promotes the release of active, full-length CF6 from endothelial cells.
• These findings reveal a novel regulatory mechanism for circulating CF6 involving inflammatory signaling.